Clinical Trials Logo

Healthy Male Participants clinical trials

View clinical trials related to Healthy Male Participants.

Filter by:
  • None
  • Page 1

NCT ID: NCT06189508 Recruiting - Clinical trials for Healthy Male Participants

A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

Start date: February 14, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, non-randomized, parallel-group, single-dose study in healthy adult male participants. The aim is to investigate the relative bioavailability (rBA) of NXT007 among subcutaneous (SC) injection sites (abdomen, upper arm, and thigh) and the absolute bioavailability (aBA) of SC NXT007 administration. In addition, the pharmacodynamic, safety, tolerability, and immunogenicity of a single dose of NXT007 following SC or intravenous (IV) administration are assessed.

NCT ID: NCT06088264 Completed - Clinical trials for Healthy Male Participants

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.

NCT ID: NCT03960502 Completed - Clinical trials for Healthy Male Participants

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Start date: May 16, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this Phase I, open-label study is to evaluate the absorption, distribution, metabolism, excretion, absolute bioavailability, and to characterize the metabolites of AG-881 in healthy male participants following administration of a single oral dose of [14C] AG-881 and a concomitant intravenous microdose of [13C315N3] AG-881.

NCT ID: NCT03922633 Completed - Clinical trials for Healthy Male Participants

A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants

Start date: April 22, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after a single intravenous dose of E3112 in Japanese healthy adult male participants.

NCT ID: NCT03444818 Completed - Clinical trials for Healthy Male Participants

A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants

Start date: April 17, 2018
Phase: Phase 1
Study type: Interventional

This study will be conducted to evaluate the absorption, metabolism, and excretion of a single oral dose of [14C]-E6007 in healthy male participants.

NCT ID: NCT01707342 Completed - Clinical trials for Healthy Male Participants

A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients

Start date: October 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the absolute bioavailability and pharmacokinetics (what the body does to the medication) of simeprevir (TMC435) after administration of single oral doses of 50 mg and 150 mg when administered together with a single intravenous (IV) dose of 100 microgram [3H]-TMC435 in healthy male participants.